The similar phenotypic effects of specific DR4 receptor internalization during long period of combined treatment with TRAIL and bortezomib was observed in breast cancer cells MDA-MB-231where almost 5 fold reduction of DR4 receptor on the cell surface was observed after 24 h incubation (Fig. S2). This evidence concerns the gene TNFSF10 and breast carcinoma.